Anti-obesity drugs: an inventor's perspective
This article was originally published in Scrip
Executive Summary
After years of anti-obesity disappointments, Orexigen's Contrave, Vivus's Qnexa and Arena's lorcaserin stand on the verge of being filed with the US FDA. Professor Michael Cowley, inventor of Contrave and former chief scientific officer of Orexigen, speaks with Scrip's Asher Mullard about his views on the obesity field.